Benjamin Cravatt

Co-Founder at Vividion Therapeutics, Inc.

Benjamin Cravatt

Benjamin Cravatt

Co-Founder at Vividion Therapeutics, Inc.

Overview
Career Highlights

Vividion Therapeutics, Inc.
ActivX Biosciences, Inc.
Pretzel Therapeutics, Inc.

RelSci Relationships

1685

Number of Boards

16

Relationships
RelSci Relationships are individuals Benjamin Cravatt likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Cardinal Partners

Relationship likelihood: Strong

Venture Partner at ARCH Venture Partners

Relationship likelihood: Strong

Venture Partner at ARCH Venture Partners

Relationship likelihood: Strong

Venture Partner at ARCH Venture Partners

Relationship likelihood: Strong

Venture Partner at Third Rock Ventures LLC

Relationship likelihood: Strong

Managing Director at ARCH Venture Partners LP

Relationship likelihood: Strong

Chairman, Department of Chemistry at The Scripps Research Institute - California

Relationship likelihood: Strong

Chairman & President at ActivX Biosciences, Inc.

Relationship likelihood: Strong

Venture Partner at Versant Venture Management LLC

Relationship likelihood: Strong

Paths to Benjamin Cravatt
Potential Connections via
Relationship Science
You
Benjamin Cravatt
Co-Founder at Vividion Therapeutics, Inc.
Education
BA in History

Stanford University, located between San Francisco and San Jose in the heart of California's Silicon Valley, is one of the world's leading teaching and research universities. Since its opening in 1891, Stanford has been dedicated to finding solutions to big challenges and to preparing students for leadership in a complex world.

PhD

The Scripps Research Institute (TSRI), one of the world's largest, private, non-profit research organizations, stands at the forefront of basic biomedical science, a vital segment of medical research that seeks to comprehend the most fundamental processes of life. Over the last decades, the institute has established a lengthy track record of major contributions to the betterment of health and the human condition. The institute — which is located on campuses in La Jolla, California, and Jupiter, Florida — has become internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases, virology, and synthetic vaccine development. Particularly significant is the institute's study of the basic structure and design of biological molecules; in this arena TSRI is among a handful of the world's leading centers. The institute’s educational programs are also top-rate. The Kellogg School of Science and Technology is currently ranked among the best in the nation in its fields of biology and chemistry. Rather than isolating faculty members, students, and laboratories into separate and distinct disciplines, as is generally prescribed in universities, a cooperative, collaborative spirit is encouraged and embraced. While the level of scientific investigation is intense, the atmosphere is collegial, relaxed, and informal. Technicians, postdoctoral fellows, graduate students, and administrative support staff all are considered part of the team and are given the latitude and responsibility to accomplish their tasks so as to serve the best interests of science. The pursuit of scientific excellence is paramount and all efforts are directed toward that end. The bulk of the institute's funding is derived from the National Institutes of Health and other federal agencies. In today's environment of increasing competition for shrinking federal dollars, however, collaborative industrial partnerships with leading pharmaceutical companies provide additional funding in several areas key to the organization's research objectives. The Scripps Research Institute's adherence to the highest scientific standards, emphasis on a multidisciplinary approach to problem solving, participation in the perpetuation of knowledge through education, and continual pursuit of research excellence provide an unparalleled scientific environment.

Memberships
Career History
Scientific Advisor
Prior

5AM Ventures invests in next-generation life sciences companies located in the US. The firm targets companies operating in the fields of biopharmaceutical, drug delivery technologies and research instruments. They provides financing for early stage and corporate spin-out capital requirements with an investment size ranging from $20 to $30 million and also makes co-investments.

Professor, Department of Chemistry
Current

The Scripps Research Institute (TSRI), one of the world's largest, private, non-profit research organizations, stands at the forefront of basic biomedical science, a vital segment of medical research that seeks to comprehend the most fundamental processes of life. Over the last decades, the institute has established a lengthy track record of major contributions to the betterment of health and the human condition. The institute — which is located on campuses in La Jolla, California, and Jupiter, Florida — has become internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases, virology, and synthetic vaccine development. Particularly significant is the institute's study of the basic structure and design of biological molecules; in this arena TSRI is among a handful of the world's leading centers. The institute’s educational programs are also top-rate. The Kellogg School of Science and Technology is currently ranked among the best in the nation in its fields of biology and chemistry. Rather than isolating faculty members, students, and laboratories into separate and distinct disciplines, as is generally prescribed in universities, a cooperative, collaborative spirit is encouraged and embraced. While the level of scientific investigation is intense, the atmosphere is collegial, relaxed, and informal. Technicians, postdoctoral fellows, graduate students, and administrative support staff all are considered part of the team and are given the latitude and responsibility to accomplish their tasks so as to serve the best interests of science. The pursuit of scientific excellence is paramount and all efforts are directed toward that end. The bulk of the institute's funding is derived from the National Institutes of Health and other federal agencies. In today's environment of increasing competition for shrinking federal dollars, however, collaborative industrial partnerships with leading pharmaceutical companies provide additional funding in several areas key to the organization's research objectives. The Scripps Research Institute's adherence to the highest scientific standards, emphasis on a multidisciplinary approach to problem solving, participation in the perpetuation of knowledge through education, and continual pursuit of research excellence provide an unparalleled scientific environment.

Co-Founder
2011 - Prior

Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.

Boards & Committees
Member, Board of Directors
2020 - Current

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Member, Scientific Advisory Board
2020 - Current

Lodo Therapeutics Corp. engages in the development of novel therapeutics from its metagenomics-based small molecule discovery platform. Its Lodo platform leverages breakthroughs in next-generation sequencing (NGS), artificial intelligence (AI), and machine learning (ML), along with advances in synthetic biology and automation. The company was founded by Sean Brady and David L. Pompliano and is headquartered in New York, NY.

Director
2020 - Current

Autobahn Therapeutics, Inc. is a thyromimetics drug discovery company. It serves patients with neurodegenerative disorders. The company is headquartered in San Diego, CA.

Member, Ivy Brain Tumor Center Scientific Advisory Board
2020 - Current

Barrow Neurological Institute is a nonprofit company headquartered in Phoenix, AZ. The firm operates hospitals for neurological patients.

Member, Scientific Advisory Board
Current

St. Jude is unlike any other pediatric treatment and research facility. Discoveries made here have completely changed how the world treats children with cancer and other catastrophic diseases. With research and patient care under one roof, St. Jude is where some of today's most gifted researchers are able to do science more quickly. The mission of St. Jude Children’s Research Hospital is to advance cures, and means of prevention, for pediatric catastrophic diseases through research and treatment. Consistent with the vision of our founder Danny Thomas, no child is denied treatment based on race, religion or a family's ability to pay. Our vision is to be the world leader in advancing the treatment and prevention of catastrophic diseases in children. This vision will be pursued by providing outstanding patient care; by conducting basic, translational and clinical research designed to elucidate biological mechanisms, understand disease pathogenesis, improve diagnosis, enhance treatment outcome, prevent diseases and minimize adverse consequences of treatment; and by educating health care and scientific research professionals. Through these efforts we seek to cure and enhance the quality of life for an increasing proportion of children who come to us for treatment, and by expanding and sharing knowledge, to advance treatment of children with catastrophic diseases worldwide, while developing strategies to prevent catastrophic diseases in children.

Board Member
Prior

The Scripps Research Institute (TSRI), one of the world's largest, private, non-profit research organizations, stands at the forefront of basic biomedical science, a vital segment of medical research that seeks to comprehend the most fundamental processes of life. Over the last decades, the institute has established a lengthy track record of major contributions to the betterment of health and the human condition. The institute — which is located on campuses in La Jolla, California, and Jupiter, Florida — has become internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases, virology, and synthetic vaccine development. Particularly significant is the institute's study of the basic structure and design of biological molecules; in this arena TSRI is among a handful of the world's leading centers. The institute’s educational programs are also top-rate. The Kellogg School of Science and Technology is currently ranked among the best in the nation in its fields of biology and chemistry. Rather than isolating faculty members, students, and laboratories into separate and distinct disciplines, as is generally prescribed in universities, a cooperative, collaborative spirit is encouraged and embraced. While the level of scientific investigation is intense, the atmosphere is collegial, relaxed, and informal. Technicians, postdoctoral fellows, graduate students, and administrative support staff all are considered part of the team and are given the latitude and responsibility to accomplish their tasks so as to serve the best interests of science. The pursuit of scientific excellence is paramount and all efforts are directed toward that end. The bulk of the institute's funding is derived from the National Institutes of Health and other federal agencies. In today's environment of increasing competition for shrinking federal dollars, however, collaborative industrial partnerships with leading pharmaceutical companies provide additional funding in several areas key to the organization's research objectives. The Scripps Research Institute's adherence to the highest scientific standards, emphasis on a multidisciplinary approach to problem solving, participation in the perpetuation of knowledge through education, and continual pursuit of research excellence provide an unparalleled scientific environment.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$100 +
2014

PROTECTION OF OUTSTANDING RIVER ECOSYSTEMS IN THE WESTERN UNITED STATES.

$100 +
2013

PROTECTION OF OUTSTANDING RIVER ECOSYSTEMS IN THE WESTERN UNITED STATES.

$100 +
2012

PROTECTION OF OUTSTANDING RIVER ECOSYSTEMS IN THE WESTERN UNITED STATES.

Investments
Details Hidden

Pretzel Therapeutics, Inc. engages in the development of novel cancer therapeutics. Its based on the role of extra chromosomal DNA (ecDNA) in driving tumorigenesis, resistance, and recurrence. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt and Jonathan E. Lim and is headquartered in San Diego, CA.

Details Hidden

Vividion Therapeutics, Inc. operates as a biotechnology company. It focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke in 2014 and is headquartered in Princeton, NJ.

Details Hidden

Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Benjamin Cravatt. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Benjamin Cravatt's profile does not indicate a business or promotional relationship of any kind between RelSci and Benjamin Cravatt.